Clin Exp DermObservational study
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.
Napolitano M, Lauletta G, Cimmino M, Girolomoni G, Pezzolo E, Ferrucci SM, Narcisi A, Borghi A, Del Duca E, Romanelli M, Bonzano L, Gori N, Peris K, Mandato F, Errichetti E, Esposito M, Marasca C, Rossi M, Zerbinati N, Galdo G, Peduto T, Ribero S, Ortoncelli M, Macagno N, Mariano M, Fargnoli MC, Di Sessa I, Gola M, Milanesi N, Caroppo F, Scotto di Luzio G, Calzari P, Maurelli M, Luyo Saboya RA, Schettini N, Gargiulo L, Bianco M, Dattola A, Manzo Margiotta F, Triolo S, Fratton Z, Carugno A, di Vico F, Patruno C
Clinical and Experimental DermatologyIn the feed 9 Jul 2026, published online 9 Jul 2026, issue 2026 Jul 09, added to PubMed 9 Jul 2026
Topics: Atopic dermatitis & eczemaOlder adultsBiologics
Abstract
Lebrikizumab, a monoclonal antibody targeting interleukin-13, has demonstrated efficacy and safety in adults with moderate-to-severe atopic dermatitis (AD), but data in elderly patients remain limited. We conducted a retrospective multicentre study including 90 patients aged ≥60 years with moderate-to-severe AD treated with lebrikizumab across 23 Italian dermatology centres. Clinical outcomes were assessed at baseline and at weeks (W)16, W24 and W52. Mean EASI decreased from 23.24 ± 7.93 at baseline to 6.33 ± 6.54 at W16, 3.57 ± 3.74 at W24 and 2.70 ± 4.83 at W52 (p < 0.0001). EASI75 was achieved by 58.4%, 82.0% and 87.0% of patients at W16, W24 and W52, respectively. Clinical responses were similar across age groups and independent of prior biologic or JAK inhibitor exposure. Adverse events occurred in 7.8% of patients and were mainly mild. These findings support the effectiveness and safety of lebrikizumab in elderly patients with AD in real-world clinical practice.
Abstract from PubMed
PMID 42423183 · DOI 10.1093/ced/llag285